IMDELLTRA® (tarlatamab-dlle) U.S. Indication IMDELLTRA ® (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease ...

CHICAGO, IL, USA I June 2, 2025 I ImmuneOncia Therapeutics, Inc. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial ...

HOUSTON, TX, USA and CHICAGO, IL, USA I May 29, 2025 I RBL LLC, a pioneering biotech venture creation studio dedicated to rapidly building companies based on ...

SEOUL, South Korea I June 02, 2025 I ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S.

This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing. IMforte [NCT05091567] is a Phase III, open-label, randomized trial evaluating the ...

Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitor ...

Preclinical data show that Sail’s eRNA vaccine candidates induce robust anti-malaria immune responses and protect against infection in a mouse challenge model ...

PASADENA, CA, USA I June 02, 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a ...

NEW YORK, NY, USA and MAINZ, GERMANY I May 28, 2025 I Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that they ...

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China ...

PARIS, France and CAMBRIDGE, MA, USA I June 2, 2025 I Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical ...

BASEL, Switzerland I June 1, 2025 I Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety ...